Clinical Trial Update: Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy [Phase 1]

View source ↗

Summary

Phase 1 study update indicates safety and tolerability of MS-R001 in patients with Diabetic Macular Edema due to Diabetic Retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• MS-R001

Snippet

Sponsor: Santen Inc. | Conditions: Diabetic Macular Edema, Diabetic Retinopathy | Phase 1 | Status: COMPLETED